Literature DB >> 33329860

Validity and reliability of the Patient Activation Measure® (PAM®)-13 Malay version among patients with Metabolic Syndrome in primary care.

N H Bahrom1, A S Ramli2, M R Isa3, N Baharudin4, S F Badlishah-Sham5, M S Mohamed-Yassin4, H Abdul-Hamid6.   

Abstract

INTRODUCTION: The Patient Activation Measure (PAM) is one of the most extensively used, widely translated, and tested instruments worldwide in measuring patient activation levels in self-management. This study aimed to determine the validity and reliability of the PAM-13 Malay version among patients with Metabolic Syndrome (MetS) attending a primary care clinic.
METHODS: This work is a cross-sectional validation study among patients with MetS attending a university primary care clinic in Selangor. The PAM-13 Malay version underwent a validation process and field testing. Psychometric properties were examined using principal component analysis (PCA) with varimax rotation, scree plot, Monte Carlo simulation, internal consistency, and test-retest reliability analyses.
RESULTS: The content of the PAM-13 Malay version and the original version were conceptually equivalent. The questionnaire was refined after face validation by 10 patients with MetS. The refined version was then field-tested among 130 participants (response rate 89.7%). The Kaiser-Meyer-Olkin test was 0.767, and Bartlett's test of sphericity was ≤0.001, indicating sampling adequacy. Two factors were identified and labeled as (1) Passive and Building Knowledge, and (2) Taking Action and Maintaining Behavior. These labels were chosen as they were conceptually consistent with the items representing the levels of activation in PAM-13. The validated PAM-13 Malay version consisted of 13 items, framed into two domains. The overall Cronbach's α was 0.79, and the intraclass correlation coefficient was 0.45.
CONCLUSIONS: The PAM-13 Malay version is valid, reliable, and fairly stable over time. This questionnaire can be used to evaluate the levels of activation among patients with MetS in primary care in Malaysia. © Academy of Family Physicians of Malaysia.

Entities:  

Keywords:  Malaysia; metabolic syndrome; patient activation; primary care; validation

Year:  2020        PMID: 33329860      PMCID: PMC7735884     

Source DB:  PubMed          Journal:  Malays Fam Physician        ISSN: 1985-2274


  33 in total

1.  Improving primary care for patients with chronic illness.

Authors:  Thomas Bodenheimer; Edward H Wagner; Kevin Grumbach
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

2.  Cultural adaptation and validation of the Brazilian Version of the Patient Activation Measure-22 items.

Authors:  Cristiane Martins Cunha; Eliane Nepomuceno; Rafaela de Oliveira Manzato; Débora Cristine Prévide Teixeira da Cunha; Dirceu da Silva; Rosana Aparecida Spadoti Dantas
Journal:  Rev Bras Enferm       Date:  2018 Jul-Aug

3.  When patient activation levels change, health outcomes and costs change, too.

Authors:  Jessica Greene; Judith H Hibbard; Rebecca Sacks; Valerie Overton; Carmen D Parrotta
Journal:  Health Aff (Millwood)       Date:  2015-03       Impact factor: 6.301

4.  The Patient Activation Measure: a validation study in a neurological population.

Authors:  Tanya L Packer; George Kephart; Setareh Ghahari; Åsa Audulv; Joan Versnel; Grace Warner
Journal:  Qual Life Res       Date:  2015-01-06       Impact factor: 4.147

5.  Development of the Patient Activation Measure for mental health.

Authors:  Carla A Green; Nancy A Perrin; Michael R Polen; Michael C Leo; Judith H Hibbard; Martin Tusler
Journal:  Adm Policy Ment Health       Date:  2009-08-29

6.  Psychometric properties of the hebrew translation of the patient activation measure (PAM-13).

Authors:  Racheli Magnezi; Saralee Glasser
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

7.  Psychometric evaluation of the German version of the Patient Activation Measure (PAM13).

Authors:  Jördis M Zill; Sarah Dwinger; Levente Kriston; Anja Rohenkohl; Martin Härter; Jörg Dirmaier
Journal:  BMC Public Health       Date:  2013-10-30       Impact factor: 3.295

8.  Measuring patient activation in The Netherlands: translation and validation of the American short form Patient Activation Measure (PAM13).

Authors:  Jany Rademakers; Jessica Nijman; Lucas van der Hoek; Monique Heijmans; Mieke Rijken
Journal:  BMC Public Health       Date:  2012-07-31       Impact factor: 3.295

9.  Validation of the German version of the patient activation measure 13 (PAM13-D) in an international multicentre study of primary care patients.

Authors:  Katja Brenk-Franz; Judith H Hibbard; Wolfram J Herrmann; Tobias Freund; Joachim Szecsenyi; Sima Djalali; Claudia Steurer-Stey; Andreas Sönnichsen; Fabian Tiesler; Monika Storch; Nico Schneider; Jochen Gensichen
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

10.  The EMPOWER-SUSTAIN e-Health Intervention to improve patient activation and self-management behaviours among individuals with Metabolic Syndrome in primary care: study protocol for a pilot randomised controlled trial.

Authors:  Maryam Hannah Daud; Anis Safura Ramli; Suraya Abdul-Razak; Mohamad Rodi Isa; Fakhrul Hazman Yusoff; Noorhida Baharudin; Mohamed Syarif Mohamed-Yassin; Siti Fatimah Badlishah-Sham; Azlina Wati Nikmat; Nursuriati Jamil; Hapizah Mohd-Nawawi
Journal:  Trials       Date:  2020-04-05       Impact factor: 2.279

View more
  2 in total

1.  Test-Retest Reliability of the Patient Activation Measure-13 in Adults with Substance Use Disorders and Schizophrenia Spectrum Disorders.

Authors:  Katrine Melby; Mona Nygård; Mathias Forsberg Brobakken; Rolf W Gråwe; Ismail Cüneyt Güzey; Solveig Klæbo Reitan; Einar Vedul-Kjelsås; Jørn Heggelund; Mariela Loreto Lara-Cabrera
Journal:  Int J Environ Res Public Health       Date:  2021-01-29       Impact factor: 3.390

2.  Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above.

Authors:  Zsombor Zrubka; Péter Vékás; Péter Németh; Ágota Dobos; Ottó Hajdu; Levente Kovács; László Gulácsi; Judith Hibbard; Márta Péntek
Journal:  Eur J Health Econ       Date:  2022-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.